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ABSTRACT Group B Streptococcus (GBS) causes serious neonatal infection via verti-
cal transmission. The prenatal GBS screening test is performed at the late stage of
pregnancy to avoid risks of infection. In this test, enrichment culture is performed,
followed by GBS identification. Selective medium is used for the enrichment; how-
ever, Enterococcus faecalis, which is a potential contaminant in swab samples, can
interfere with the growth of GBS. Such bacterial contamination can lead to false-neg-
ative results. Endolysin, a bacteriophage-derived enzyme, degrades peptidoglycan in
the bacterial cell wall; it is a promising antimicrobial agent for selectively eliminating
specific bacterial genera/species. In this study, we used the recombinant endolysin
EG-LYS, which is specific to E. faecalis; the endolysin potentially enriched GBS in the
selective culture. First, in the false-negative model (coculture of GBS and E. faecalis,
which disabled GBS detection in the subsequent GBS identification test), EG-LYS
treatment at 0.1mg/ml improved GBS detection. Next, we used 548 vaginal swabs
to test the efficacy of EG-LYS treatment in improving GBS detection. EG-LYS treat-
ment (0.1mg/ml) increased the GBS-positive ratio to 17.9%, compared to 15.7% in
the control (phosphate-buffered saline [PBS] treatment). In addition, there were an
increased number of GBS colonies under EG-LYS treatment in some samples. The
results were supported by the microbiota analysis of the enriched cultures. In con-
clusion, EG-LYS treatment of the enrichment culture potentially improves the accu-
racy of the prenatal GBS screening test.
IMPORTANCE Endolysin is a bacteriophage-derived enzyme that degrades the pepti-
doglycan in the cell wall of host bacteria; it could be used as an antimicrobial agent
for selectively eliminating specific bacterial genera/species. Group B Streptococcus
(GBS) causes neonatal infection via vertical transmission; prenatal GBS screening test,
in which enrichment culture is followed by bacterial identification, is used to detect
the presence of GBS in pregnant women. However, the presence of commensal bac-
teria such as Enterococcus faecalis in clinical specimens can inhibit GBS growth in the
selective enrichment culture, resulting in false-negative result. Here, we demon-
strated that the application of originally isolated endolysin in the enrichment culture
improved the test accuracy by inhibiting unwanted E. faecalis growth and therefore
avoiding false-negative results, not only in experimental settings, but also in tests
using vaginal swabs.
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S treptococcus agalactiae or group B Streptococcus (GBS) is often transmitted verti-cally from pregnant women to newborns during delivery, potentially leading to
fatal neonatal infections such as sepsis, pneumonia, or meningitis (1, 2). To avoid the
risk of infection, a GBS culture test is often performed during the late stage of preg-
nancy (1, 2), and prophylactic antibiotics are prescribed to GBS-positive pregnant
women (1, 2). In the prenatal GBS screening test, the enrichment culture of a vaginal
and anorectal swab is followed by a bacterial identification test to improve GBS detec-
tion (3, 4). The GBS identification test is carried out using culture-based and/or nucleic
acid amplification tests (4). The selective culture media used for GBS enrichment, such
as Granada broth and Lim broth, are formulated to minimize the growth of bacteria
other than GBS (5, 6). However, Enterococcus faecalis growth in GBS cultures disturbs
the growth of GBS, possibly leading to false-negative results (7–9). The culture-based
bacterial identification tests, following enrichment culture, have a false-negative rate
of approximately 3 to 7% (10, 11). To reduce cases of GBS infection in neonates, it is im-
portant to improve the test accuracy by inhibiting the growth of E. faecalis in the
enrichment culture.
Bacteriophages (phages) specifically infect bacterial cells through compatible recep-
tors or growth-supporting systems. Most phages are highly host-specific, infecting
only a particular species or genera (12). Once phages infect the host bacterial cells,
they propagate within the cells and release progeny phages into the milieu. In the late
stage of phage infection, endolysin, a peptidoglycan-hydrolyzing enzyme encoded by
the phage genome, plays a crucial role in the hydrolysis of the peptidoglycan network,
facilitating the release of progeny phages (13, 14). The specificity of endolysin is limited
to specific bacterial genera and/or species; however, it generally has broader specificity
than phages because it is not influenced by bacterial host immunity (15, 16). Phages
and endolysin could be used to inhibit unwanted E. faecalis growth.
We previously reported the use of an E. faecalis-specific phage cocktail as an E. faecalis
selective growth inhibitor in the prenatal GBS screening test (17). However, the introduc-
tion of this phage cocktail for clinical use in prenatal GBS screening tests could be limited
by the following factors: (i) phages in the mixture must be monitored consistently because
phage-insensitive or -resistant bacteria could emerge (18); (ii) the phage cocktail needs to
be optimized, as the phages in the cocktail may interfere with each other (19); (iii) it may
take longer than expected to prepare the phage cocktail, because the process for manufac-
turing each phage requires optimization (20); and (iv) the use of phages in clinical laborato-
ries may cause phage contamination in clinical specimens (17).
The use of endolysin is considered to overcome these issues and has the following
advantages over phage cocktail in the prenatal GBS screening test: (i) a single endolysin
alone is likely to cover a broader range of target bacterial strains than a single phage, and
therefore the process development of endolysin manufacturing requires less effort than
that for the phage cocktail (13, 21); (ii) emergence of endolysin-resistant mutants is more
unlikely than the emergence of phage-resistant bacteria (13); and (iii) recombinant endoly-
sin is commercially available for therapeutic purposes (22), and therefore the exploration of
its use in prenatal GBS screening test saves time and money.
We hypothesized that the use of endolysin could improve the prenatal GBS screen-
ing test by reducing the number of false-negative results caused by E. faecalis in the
enrichment culture. In this study, we tested the potential of endolysin in the enrich-
ment culture followed by culture-based identification tests for reducing the number of
false-negative results by suppressing E. faecalis growth in the prenatal GBS screening
test using clinical specimens.
RESULTS AND DISCUSSION
Recombinant endolysin of phage phiM1EF2. We isolated the E. faecalis phage
phiM1EF2, which belongs to the family Siphoviridae and genus Saphexavirus, based on
its genome sequence similarity to phages belonging to this family. Open reading frame
60 (ORF60) consisted of 237 amino acids containing the CHAP domain, which was
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estimated to be 26.1 kDa. ORF60 is an amidase, and therefore it was predicted to be an
endolysin. Recombinant ORF60 fused with a 6His tag at the C-terminal end was pro-
duced in Escherichia coli and purified using affinity chromatography (see Fig. S1A in
the supplemental material). The enzymatic activity was tested spectrophotometrically
using peptidoglycan extracted from E. faecalis KUEF29 as the substrate in phosphate-
buffered saline (PBS; pH 7.4). The enzyme decreased the turbidity in a dose- and time-
dependent manner (see Fig. S1B in the supplemental material). We tentatively desig-
nated the purified recombinant protein ORF60 as EG-LYS.
EG-LYS activity was examined using E. faecalis, Enterococcus faecium, Enterococcus
avium, and GBS strains isolated from the vaginal swabs in the prenatal GBS screening
test (17). First, EG-LYS activity on peptidoglycan and whole bacterial cells in PBS was
analyzed. The reaction velocity of EG-LYS on peptidoglycan and whole bacteria
(change in optical density at 595m nm [DOD595]/min/mg protein) was examined, and it
was calculated as the difference in turbidity reduction between EG-LYS and PBS treat-
ments divided by the incubation period and the amount of EG-LYS used (Fig. 1A). The
reaction velocities of EG-LYS on Escherichia coli DH5a cells were used as negative con-
trols (mean 6 standard deviation [SD]; 20.07986 0.0675 DOD595/min/mg). The reac-
tion velocities of EG-LYS on the peptidoglycan and intact cells of E. faecalis
(0.18016 0.0658 and 0.38086 0.1798 DOD595/min/mg, respectively) were significantly
higher than that in the negative control. However, the reaction velocities of EG-LYS on
the peptidoglycan and intact cells of E. faecium, E. avium, and GBS were nearly indistin-
guishable from that in the negative control.
Moreover, we examined the growth-inhibitory efficacy of EG-LYS treatment
(Dlog10CFU/h/mg), which was calculated as the difference in bacterial growth between
EG-LYS and PBS treatments divided by the incubation period and amount of EG-LYS
used (Fig. 1B). The growth inhibitory efficacies on E. faecalis (mean 6 SD, 40.326 24.27
Dlog10CFU/h/mg) were higher than those against the other tested bacterial strains,
including E. avium, E. faecium, and GBS (24.276 3.47 Dlog10CFU/h/mg).
These results indicated that EG-LYS specifically inhibited the growth of E. faecalis by
degrading its peptidoglycan.
Construction of the false-negative model by coculturing GBS and E. faecalis. To
test whether EG-LYS treatment suppresses E. faecalis growth and improves GBS detection,
a false-negative model is essential. GBS strain KUGBS2rif at 102 CFU/ml was cocultured
with E. faecalis strain KUEF29 at 102, 103, 104, or 105 CFU/ml in Granada broth, and the cul-
ture broth was streaked on Granada and commercial chromogenic agars. KUGBS2rif was
detected in the enriched broth inoculated with 102 and 103 CFU/ml KUEF29; however, it
was not detected in enriched broth inoculated with 104 and 105 CFU/ml KUEF29 (Fig. 2A).
GBS efficiently produces pigments under anaerobic conditions (23), and therefore the incu-
bation was not the most suitable condition for GBS detection. However, GBS detection was
comparable between the cultures on Granada agar and commercial chromogenic agar,
based on colony color under these conditions. In addition, we analyzed the bacterial cell
densities in these coculture samples after enrichment and found that KUGBS2rif densities
were the lowest when KUEF29 inoculation densities ranged between 104 and 105 CFU/ml
(Fig. 2B). KUGBS2rif densities increased gradually as KUEF29 inoculation density decreased
to 103 to 102 CFU/ml. Thus, the coculture of single strains of KUEF29 at 104 CFU/ml and
KUGBS2rif at 102 CFU/ml at inoculation was used as a false-negative model. In addition,
the coculture of single strains of E. faecalis at 104 CFU/ml and GBS at 102 CFU/ml at inocula-
tion was examined using 7 and 30 strains of GBS and E. faecalis, respectively. Upon testing
210 pairs of single strains of GBS and E. faecalis, GBS detection failed in all combinations
(see Table S1 in the supplemental material). Therefore, the coculture of single strains of E.
faecalis at 104 CFU/ml and GBS at 102 CFU/ml at inoculation was used as a false-negative
model.
Effect of EG-LYS treatment on GBS detection in the false-negative coculture
model. Different concentrations of EG-LYS (0.1, 0.01, and 0.001mg/ml) were tested in
the false-negative model with strains KUGBS2rif and KUEF29. We examined the appear-
ance of GBS colonies on Granada agars after enrichment culture (Fig. 3A) and found
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that GBS colonies were detected from the samples treated with 0.1 and 0.01mg/ml of
EG-LYS, whereas they were undetectable from the culture treated with 0.001mg/ml of
EG-LYS and in the PBS-treated control. In addition, we measured the bacterial densities
in the enrichment culture and found that the density of KUGBS2rif was approximately
109 to 1010 CFU/ml in the EG-LYS treatment culture (0.1 and 0.01mg/ml), whereas it
was approximately 105 to 106 CFU/ml in the EG-LYS (0.001mg/ml) and PBS treatment
cultures (Fig. 3B). We also monitored the change in the bacterial densities over time;
EG-LYS treatment at 0.1 and 0.01mg/ml showed that the growth of KUEF29 was sup-
pressed during the initial 3 h of incubation, possibly enabling the growth of GBS cells
(see Fig. S2 in the supplemental material).
In the aforementioned 210 pairs of false-negative models, EG-LYS treatment at 0.1
and 0.01mg/ml showed a GBS detection rate of 99.0% (208 out of 210 pairs) and
59.0% (114 out of 210 pairs), respectively (see Table S1 in the supplemental material).
The reduction in EG-LYS concentration from 0.1 to 0.01mg/ml approximately halved
the E. faecalis-inhibitory effect. These results strongly indicate that EG-LYS treatment is
useful in improving GBS detection. Considering these results, we used an EG-LYS con-
centration of 0.1mg/ml in further experiments.
Verification of EG-LYS treatment in prenatal GBS screening test using vaginal
swabs. Using 548 vaginal swabs collected at a clinical laboratory for unknown purposes,
the effect of EG-LYS treatment on GBS detection was tested. The swabs were resuspended
in a small volume of Granada broth, dispensed into a pair of Granada broths; one tube sup-
plemented with EG-LYS at 0.1mg/ml and the other with an equal volume of PBS. Tubes
were incubated at 37°C for 24 h, and the enriched cultures were then streaked onto chro-
mogenic agars, followed by colony identification using mass spectrometry. Bacterial colo-
nies were observed in 371 samples, yet none were observed in the culture of the remain-
ing 177 samples. Among the 371 samples, 98 and 86 samples were GBS-positive in EG-LYS
and PBS treatment, respectively. Thus, the GBS detection ratio in EG-LYS-treated culture
FIG 1 EG-LYS activity in vitro. (A) Reaction velocities of EG-LYS on peptidoglycan and bacterial cells.
The reaction velocity in change of optical density at 595 nm (DOD595)/min/mg was calculated from
the difference in turbidity change between EG-LYS and phosphate-buffered saline (PBS) treatments
divided by time and the amount of EG-LYS used (see Fig. S6 in the supplemental material). Each dot
represents the velocity of EG-LYS on peptidoglycan or bacterial cell and is an average of triplicate
data. Escherichia coli strain DH5a was used as a negative control, and the experiments were repeated
10 times. The mean value of the velocities of EG-LYS treatment is shown by a thick gray line. The
data were analyzed using the Kruskal-Wallis test followed by post hoc Dunn’s multiple-comparison
test. Statistical significances at P, 0.05 and P, 0.001 are shown as single (*) and double (**)
asterisks, respectively. (B) Growth-inhibitory efficiencies of EG-LYS treatment against intact bacterial
cells. The growth-inhibitory efficiency in Dlog10CFU/h/mg was calculated from the difference of
bacterial growth between EG-LYS and PBS treatments divided by incubation time and the amount of
EG-LYS used (see Fig. S7 in the supplemental material). Each dot represents the growth inhibitory
efficiency of an individual strain. The mean value is shown as a bold gray line. The data were
analyzed using the Mann-Whitney U test. Statistical significance at P, 0.0001 is denoted by a triple
asterisk (***).
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appeared to be 17.9% (98/548), whereas that in the PBS-treated culture was 15.7% (86/548
samples), consistent with the results of a culture-based prenatal GBS screening test
reported in a previous study (24). GBS-positive samples from the EG-LYS-treated culture
were consistently GBS positive in PBS-treated cultures, suggesting that the EG-LYS treat-
ment did not interfere with the test results. Improved GBS detection ratios due to EG-LYS
FIG 2 Construction of the false-negative model by coculturing GBS KUGBS2rif with Enterococcus faecalis KUEF29. GBS
KUGBS2rif at 102 CFU/ml was cocultured with E. faecalis KUEF29 at 102, 103, 104, and 105 CFU/ml in the Granada broth
at 37°C for 24 h. The enriched culture was subcultured onto the Granada agar and the commercial chromogenic agar
by stroke smear. (A) Colony appearance on Granada agar and commercial chromogenic agar. The GBS colony
appeared orange on the Granada agar (top) and red on commercial chromogenic agar (bottom). GBS was detectable
when KUGBS2rif at 102 CFU/ml was inoculated with KUEF29 at 102 and 103 CFU/ml in Granada broth, whereas it was
not detected with KUEF29 at $104 CFU/ml. (B) Bacterial cell densities in the enriched cultures. The mean and SD of
cell densities of KUGBS2rif (closed column) and total bacteria (open column) are presented with error bars (n= 3). Cell
densities of total bacteria were measured to validate the experiment. According to one-way analysis of variance
(ANOVA), no statistical difference was observed in the total bacteria (P. 0.05), while it was observed in the KUGBS2rif
(P, 0.0001). According to the following Tukey’s post hoc test, the GBS densities decreased with statistical significance,
as the inoculated densities of E. faecalis increased from 102 and 103 to 104 CFU/ml. Statistical significance is denoted
by an asterisk (*, P, 0.001).
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treatment appeared statistically significant (McNemar test, P=0.00151; Table 1), indicating
that the EG-LYS treatment reduced the ratio of false-negative results without affecting
specificity. False-negative samples accounted for approximately 2.2% (12 out of 548 sam-
ples) of the samples.
In addition to the 12 false-negative samples described above, five GBS-positive samples
showed increased number of GBS colonies on the chromogenic agar in the EG-LYS treat-
ment compared to that in the PBS treatment (see Fig. S3 in the supplemental material).
Among the 98 GBS-positive samples from the EG-LYS-treated enriched cultures, 17 samples,
which included 12 false-negative samples and five GBS-positive samples with increased num-
ber of GBS colonies, were considered to improve the GBS detection. Thus, EG-LYS treatment
contributed to an increase in GBS detection by 17.3% (i.e., 17/98 GBS-positive samples).
Note that this test has a few limitations. First, this test used vaginal swabs rather than vagi-
nal-rectal swabs. The detection rate of GBS using vaginal-rectal swabs is higher than those
using vaginal swabs, and therefore the use of vaginal-rectal swabs is recommended for better
TABLE 1 Results of clinical examination
Detection of GBS
Treatment with EG-LYS in
enrichment medium (% [no./total])
Treatment with PBS in
enrichment medium (% [no./total])
Positive 17.9 (98/548) 15.7 (86/548)
Negative 82.1 (450/548) 84.3 (462/548)
FIG 3 Effect of EG-LYS treatment in the false-negative model using GBS KUGBS2rif and E. faecalis
KUEF29. (A) Appearance of bacterial colonies on Granada agar. On Granada agar, orange colonies are
KUGBS2rif, while white colonies are KUEF29. Only E. faecalis appeared on the agar subcultured from
the enriched culture with EG-LYS treatment at 0.001mg/ml and with PBS treatment. Both KUGBS2rif
and KUEF29 appeared on the Granada agar subcultured from the enriched cultures with EG-LYS
treatments at 0.1 and 0.01mg/ml. (B) Bacterial densities of KUGBS2rif and total bacteria in enrichment
cultures with PBS and EG-LYS treatments. The false-negative model was treated with EG-LYS at 0.1,
0.01, and 0.001mg/ml. As a negative control, the enriched culture with PBS treatment was used. The
means and SD of bacterial densities are presented as column charts with error bars (n= 6). According
to one-way ANOVA, no statistical difference was observed among the tested groups in the total
bacteria (P. 0.05), while it was observed in the KUGBS2rif strain (P, 0.0001). According to the
following Tukey’s post hoc test, the GBS densities increased with statistical significance, as the EG-LYS
treatment increased from 0.001mg/ml to 0.01 and 0.1mg/ml. Statistical significance is denoted by an
asterisk (*, P, 0.001).
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GBS recovery (4, 25). Second, fresh vaginal swab samples were not used. To accurately evalu-
ate the effects of EG-LYS treatment in the clinical setting, the vaginal-rectal swab samples
should be used in the culture-based prenatal GBS screening tests within 24 h. Third, the vagi-
nal swabs were not collected for prenatal GBS screening test.
Effect of EG-LYS treatment on the microbiota of enriched cultures. The effects
of EG-LYS treatment on the microbiota of enrichment culture were examined. The
microbiota of the above-mentioned 17 samples were compared between the EG-LYS
and PBS treatments. Seventeen pairs of one preculture sample and two postculture
samples of EG-LYS and PBS treatments were analyzed using 16S rRNA amplicon
sequencing. A total of 51 sequencing data (1,850,335 reads in total; 36,2816 6,578
reads/sequencing data) were obtained (see Fig. S4 in the supplemental material).
Analysis of the microbial diversity indicated that there was no significant difference in
the species richness between the PBS and EG-LYS treatments in the enrichment culture
(Fig. 4); however, EG-LYS and PBS treatments caused phylogenetic changes in the bac-
terial community.
Moreover, the bacterial taxa that were significantly abundant in the enriched cul-
ture broths treated with EG-LYS and PBS were analyzed (Table 2). Bacterial taxa
with,0.01% of relative abundance were classified together; 28 bacterial taxa at the
species level were detected in the data set. Analysis of the data set using the Wilcoxon
signed-rank test showed that only S. agalactiae and Enterococcus spp. were signifi-
cantly more and less abundant, respectively, in the EG-LYS-treated enriched cultures
than in the PBS-treated enriched cultures. EG-LYS treatment does not influence the
population of other bacterial taxa in the clinical specimens. This result was mostly con-
sistent with the results of the bacterial identification tests based on chromogenic agars
followed by mass spectrometry (see Table S2 in the supplemental material). Thus, this
microbiome analysis strongly corroborated the improvement in GBS detection using
EG-LYS treatment without being influenced by other bacterial populations in the
enrichment culture.
Perspective of endolysin use in prenatal GBS screening tests. Use of endolysin
improved GBS detection by approximately 2.2% in this study. Approximately 900 thou-
sand pregnancies were reported in Japan in 2018 (26). Assuming that GBS was
detected in approximately 2.2% of pregnancies, using EG-LYS in prenatal GBS screen-
ing tests could reduce the chances of GBS infections in 19.8 thousand neonates at risk
through prenatal and perinatal administration of antibiotics. Thus, EG-LYS treatment of
the enrichment culture in GBS testing potentially reduces the risks of GBS infection in
neonates from the relatively large population of GBS carriers by prenatal and perinatal
FIG 4 Analyses of microbial diversities of 17 pairs of swab-resuspended broth and enriched cultures
treated with PBS and EG-LYS. (A) Differences in alpha diversity of Shannon index metric between
before and after enrichments by PBS and EG-LYS treatments. No significant difference between EG-
LYS and PBS treatments was observed. (B) Changes in microbial community structures following
enrichment cultures between PBS and EG-LYS treatments. Weighted and unweighted UniFrac
distances are shown on the left and right, respectively. Statistical analysis was conducted by Wilcoxon
signed-rank test. Statistical significance is denoted by an asterisk (*, P, 0.05).
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prophylactic treatments of antibiotics. Moreover, the dissemination of drug-resistant
GBS recently reported worldwide could be reduced by use of endolysin in the prenatal
GBS screening test (27–29).
To introduce the use of endolysin as part of clinical tests, several hurdles must be
overcome. (i) The storage stability of endolysin is important for stable supply. EG-LYS
retained its potency for 6months when stored in Granada broth at 4°C (see Fig. S5 in
the supplemental material). (ii) Effective process development for endolysin can be
achieved using the quality by design (QbD) approach for maintaining product quality
(30). In the pharmaceutical industry, process development needs to be optimized by
design of experiments (DoE) (31). (iii) We used liquid culture broth for enrichment;
however, commercially available enrichment broths are typically semifluid. Application
of endolysin to such typical forms of GBS enrichment broths should be optimized for
user-friendliness. By overcoming the latter two hurdles, EG-LYS is expected to be
applied in prenatal GBS screening tests in clinical settings.
While most endolysin products were effective against Gram-positive bacteria, those
effective against Gram-negative bacteria have been recently reported (32). We hope to
extend the use of endolysin to the clinical setting.
MATERIALS ANDMETHODS
Bacteria, culture media, and reagents.We used 5, 30, 5, and 7 strains of E. avium, E. faecalis, E. fae-
cium, and GBS, respectively, which were all isolated from clinical vaginal swabs and identified using
mass spectrometry (17). In the case of GBS strains, the Lancefield B antigens were also tested using a kit
(Strept LA “SEIKEN”; Denka Company, Niigata, Japan). In addition, we used E. faecalis ATCC 29212,
Escherichia coli DH5a, E. coli NiCo21 (DE3) (New England BioLabs, Ipswich, MA), and a rifampin-resistant
GBS KUGBS2rif strain derived from GBS KUGBS2 cultured in tryptic soy agar (TSA) supplemented with
20mg/ml rifampin.
The enterococcal and streptococcal strains were cultured in tryptic soy broth (TSB) or TSA unless oth-
erwise stated, while E. coli was cultured in Luria-Bertani media (LB medium [Miller]; Kanto Chemical Co.,
Tokyo, Japan).
Granada broth (25.0 g/liter proteose peptone no. 3, 14.0 g/liter soluble starch, 2.5 g/liter glucose, 1.0
g/liter pyruvic acid sodium salt, 0.1 g/liter cysteine hydrochloride, 0.3 g/liter magnesium sulfate, 11.0 g/
liter 3-(N-morpholino)propane sulfonic acid, 10.7 g/liter disodium hydrogen phosphate, 0.5mg/liter crys-
tal violet, 10mg/liter colistin sulfate, 10mg/liter metronidazole, and 15mg/liter nalidixic acid [pH 7.4])
was prepared as described previously with a slight modification (17).
TSA and rifampin-supplemented TSA were used to score the total cell count and the count for strain
KUGBS2rif, respectively.
Granada agar, which was prepared by supplementing Granada broth with 1.5% (wt/vol) agar, and/or
ChromID StreptoB agars (Sysmex bioMérieux Co., Ltd., Tokyo, Japan) was used to detect GBS colonies,
based on colony pigments.
Culture media were purchased from Beckton Dickinson and Co. (Franklin Lakes, NJ) unless otherwise
stated. Other reagents were purchased from Nacalai Tesque (Kyoto, Japan) or Fujifilm Wako Pure Chemicals
(Osaka, Japan) unless otherwise stated. All bacteria were cultured aerobically at 37°C unless otherwise stated.
Phage isolation and genome sequencing. Enterococcal phages were isolated from sewage influent
water collected in Tokyo, Japan, using E. faecalis strain KUEF2 as an indicator, by a method described
elsewhere (17). Phages were purified after large-scale phage amplification, and phage genomic DNA
was isolated using methods described previously (17, 33). A shotgun library was prepared for each
phage DNA using the GS FLX Titanium rapid library preparation kit (Roche Diagnostics, Indianapolis, IN)
according to the manufacturer’s instructions. The libraries were analyzed using a GS Junior 454
sequencer (Roche Diagnostics). The sequence reads were assembled using Newbler (version 3.0; 454 Life
Sciences, Branford, CT) (34). The draft genome sequence obtained through de novo assembly of 5,153
shotgun pyrosequencing reads, 24.0 of the peak depth, was 56,582 bp.
The genome sequence was analyzed using the BLASTn tool at National Center for Biotechnology
Information (NCBI; https://blast.ncbi.nlm.nih.gov/Blast.cgi; accessed 20 January 2020). The genome was
annotated using the prokaryotic genome annotation pipeline DFAST (https://dfast.nig.ac.jp/; accessed
TABLE 2 Differential abundance analysis of microbiota in enriched cultures treated with EG-LYS and PBS
Bacterial taxonomya P Adjusted P Log2(fold change) Ordering
Firmicutes, Bacilli, Lactobacillales, Streptococcaceae,
Streptococcus agalactiae
0.00002 0.00043 22.10 EG-LYS treatment! PBS treatment
Firmicutes, Bacilli, Lactobacillales, Enterococcaceae,
Enterococcus (no species)
0.00348 0.04876 5.68 EG-LYS treatment/ PBS treatment
Other bacterial taxa .0.05 .0.7
aBacterial taxonomy is shown in the order of phylum, class, order, family, and genus and species.
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20 February 2019) (35). The predicted gene products were analyzed using the BLASTp tool at NCBI
(https://blast.ncbi.nlm.nih.gov/Blast.cgi; accessed 20 February 2019).
Cloning and protein expression. The phage phiM1EF2 sequence was amplified by PCR (HiFi DNA po-
lymerase; Kapa Biosystems, Wilmington, MA) using the primer set phiM1EF2LYS_F (59-CGGTACCCGGGGATC-
GGTACC-ATGGTTAAAGTAAACGATGTACTAAGCTATG-39) and phiM1EF2LYS_R2 (59-CGACTCTAGAGGATC-AA
GCTT-TTAATGATGATGATGATGATG-TACTTTAACTTGTGGTAAAGCTGCTTCC-39), with phage phiM1EF2 geno-
mic DNA as the template. The PCR product was cloned into pUC19 using an In-Fusion HD cloning kit (TaKaRa
Bio, Shiga, Japan). The fragment cloned accurately in pUC19 was excised with HindIII and KpnI and subcloned
into the expression vector pCold III (TaKaRa Bio). This plasmid for the recombinant ORF60 expression was des-
ignated pCold III orf60. The plasmids were used to transform E. coli strains DH5a and NiCo21 (DE3) for cloning
and protein expression, respectively.
To overexpress the recombinant protein, E. coli NiCo21 (DE3) harboring the pCold III orf60 plasmid
was exponentially grown to an optical density at 600 nm (OD600) of 0.2 to 0.3, in 250ml LB medium and
then allowed to stand for 30min on ice. The culture was supplemented with 1mM isopropyl-b-d-thioga-
lactopyranoside, and the bacteria were cultured aerobically for 36 h at 15°C. The culture was centrifuged
(10,000 g, 5min, 4°C), the cell pellets were resuspended in 25ml of lysis buffer (100mM sodium phos-
phate and 300mM NaCl [pH 7.8]), and sonicated (5-s pulses at 5-s intervals 60 times) on ice, using a
Q700 sonicator (Qsonica, Newtown, CT). The cell lysate was centrifuged (8,000 g, 10min, 4°C), and the
supernatant was incubated with gentle mixing overnight at 4°C with 250ml Co21-agarose resin
(ProteNova, Kagawa, Japan). The resin was washed with lysis buffer and then packed into an open col-
umn. The column was eluted sequentially using lysis buffer supplemented with 5mM, 50mM, 350mM,
and 500mM imidazole. The eluates of 350mM and 500mM imidazole buffer were enriched with the
recombinant proteins. The elutes were dialyzed overnight at 4°C against PBS (pH 7.4).
Protein concentration was measured using Bradford reagent (TaKaRa Bradford Protein assay kit;
TaKaRa Bio), with bovine serum albumin as the standard.
Analysis of peptidoglycan hydrolysis activity. Peptidoglycan suspensions from E. faecalis, E. fae-
cium, E. avium, and GBS were prepared as follows. An exponential-phase culture at an OD600 of 0.6 was
suspended in 4% sodium dodecyl sulfate (SDS), autoclaved (15min, 121°C), and washed six times with
deionized water. Crude peptidoglycan was suspended in PBS. Bacterial cells to be used for endolysin
substrate were grown until the mid-log phase, washed with PBS once, and suspended in PBS.
The initial turbidity of suspensions (peptidoglycan or intact cells in 100ml of PBS) in an uncoated
sterile polystyrene 96-well plate were adjusted to an optical density of 595 nm (OD595) of 0.2 to 0.3,
measured using a Multiskan JX spectrophotometer (Thermo Labsystems, Stockholm, Sweden). Serially
diluted purified recombinant protein (50ml) was added to the well at 0.1 and 0.01mg protein/ml. PBS
was used as a negative control. Plates were incubated at 37°C with stirring. Turbidity of the crude pepti-
doglycan or the cells suspended in PBS was measured at 0, 5, 15, 30, and 60min. The mean value of
three wells was used as the representative data for each treatment. The reaction velocity was measured
in DOD595/min/mg, which is defined as the turbidity reduction rate per time and the amount of protein
used, as described in Fig. S6 in the supplemental material.
Analysis of the growth inhibitory efficiency against a single bacterial species. The overnight bac-
terial culture in TSB was resuspended in double strength TSB (2TSB) at 2.0 to 3.0 104 CFU/ml. An
equal volume of counterpart bacterial suspension in 2TSB was mixed with PBS (negative control) or
the purified protein solution (0.02mg/ml). After incubation for 3 to 6 h, the viable numbers on TSA were
counted. The growth-inhibitory efficiency against each bacterium in Dlog10CFU/h/mg was calculated
from the difference in bacterial growth between EG-LYS and PBS treatments divided by the incubation
time and amount of protein used, as described in Fig. S7 in the supplemental material. The experiments
were repeated at least three times, and the mean value was obtained.
Setting of the false-negative model by coculture of E. faecalis and GBS. Bacteria were grown until
the mid-log phase (OD600 = 0.3 to 0.4) and diluted to the desired densities in Granada broth. The GBS
strain KUGBS2rif at 2.0 102 to 4.0 102 CFU/ml was cocultured with E. faecalis strain KUEF29 at
2.0  102 to 4.0 102 CFU/ml, 2.0  103 to 4.0 103 CFU/ml, 2.0  104 to 4.0 104 CFU/ml, or 2.0  105
to 4.0 105 CFU/ml. The enrichment culture was performed for 24 h in air with 5% CO2. The bacterial
densities of KUGBS2rif and total bacteria in the enriched cultures were measured using appropriate agar
media, as described above. The enriched culture was then streaked onto the Granada agar and ChromID
StreptoB agars. Following the 24 h of incubation, the growth of GBS colonies on the agars was visually
evaluated based on the color. Experiments were repeated three times.
We cocultured 210 pairs of single strains of bacteria, using 7 strains of GBS and 30 strains of E. faeca-
lis, at the inoculation bacterial density of 102 CFU/ml GBS and 104 CFU/ml E. faecalis, for 24 h in air with
5% CO2. The enriched cultures were streaked onto Granada agar and then incubated for 24 to 48 h as
described above. GBS detection was performed visually based on the color of GBS colonies. Experiments
were repeated three times.
Determining effectiveness of purified protein in the false-negative model. The purified proteins
at desired concentrations were added to the false-negative models containing 102 and 104 CFU/ml of GBS
and E. faecalis, respectively, in Granada broth. As a negative control, the purified protein was replaced with
PBS. The culture broth was incubated for 24 h in air with 5% CO2. In the false-negative model using the
strains KUGBS2rif and KUEF29, the bacterial densities in the enriched cultures were measured. The enriched
cultures were subcultured onto Granada agar by stroke smearing. After incubation in 5% CO2 for 24 to 48 h,
the appearance of colonies was visually observed, and the GBS detection was performed. Experiments were
repeated at least thrice.
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Examining the effectiveness of purified protein in clinical specimens. Residual vaginal swabs with
anonymized personal and clinical information were used in this study. The vaginal swab samples collected
from patients at the local clinical laboratory and subjected to clinical laboratory tests were used in this study.
The results of the clinical laboratory tests were not provided in this study for protection of privacy. The swabs
stored at 4°C within 1 to 2weeks following the sample collection were used.
The swabs were resuspended in 2.5ml of Granada broth and dispensed into two 0.9-ml aliquots for the
enrichment cultures. Remaining broth (approximately 0.6ml) was stored at 280°C. Before enrichment cul-
ture, 0.9ml of the swab-resuspended Granada broth was supplemented with 0.1ml of PBS or purified protein
solution and then incubated for 24 h. The enriched culture was streaked onto ChromID StreptoB agars and
incubated for 24 to 48 h. The bacterial colonies were isolated and subcultured on 5% sheep blood agar plates
(Eiken Chemical Co., Ltd., Tokyo, Japan). The isolated bacteria were identified using a microflex system
(Bruker Daltonics, Bremen, Germany). The protein profile of each bacterium was analyzed using the matrix-
assisted laser desorption ionization (MALDI) Biotyper v3.1 with the most updated spectrum library, v9 (8,468
spectra). All cultures were incubated at 35°C under aerobic conditions.
The experiment was approved by the Kitasato Institute Hospital Research Ethics Committee (approval no.
19060). The inoculated Granada broth and enriched culture broths were stored at280°C for microbiota analysis.
16S rRNA amplicon sequencing and analysis. DNA was extracted from the swab-resuspended broths
and the enriched culture broths, using an Isospin fecal DNA kit (Nippon Gene, Tokyo, Japan). The V3-V4
regions of the 16S rRNA gene were amplified by PCR and analyzed using a MiSeq instrument with a MiSeq
reagent kit v3 (600 cycles; Illumina) as described previously (36). The sequence data were processed using
Quantitative Insights Into Microbial Ecology 2 (QIIME 2) v2020.11.0 (37). The DADA2 software package
v2020.8.0 incorporated in QIIME 2 was used to correct sequence errors and construct an amplicon sequence
variant table. Microbial taxonomy was assigned using a naive Bayes classifier trained on the SILVA 138 99%
database (38). Statistical analysis was performed using R implemented in QIIME 2. The differential abundance
analysis was performed using DAtest software v2.7.12, installed in R v4.0.3 (39, 40).
Statistical analysis. Statistical analyses were performed using Prism 4 (GraphPad Software, La Jolla,
CA), or R version 4.0.3 (41). A P value of,0.05 was considered statistically significant.
Data availability. The draft genome sequence of phage phiM1EF2 was deposited in GenBank under
accession number LC547238. The sequencing data of the 16S rRNA gene (V3-V4 region) amplicons were
deposited under BioProject no. PRJDB10939.
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